SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Adolor(ADLR)Maybe the Answer to the Pain of Owning Biotechs!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: rareearth424/11/2007 5:16:49 AM
  Read Replies (1) of 21
 
Well, that was painful. I was wrong about Entereg, but in reviewing the available data, I probably would have made the same decisions again. A lot of drugs and near-drugs are having trouble because of an excess number of CV events or death in the active treatment arms of the studies....torcetrapib most recently, but also febuxostat and let's not forget about Vioxx.....

Questions I should have paid more attention to are the following:

1. Is systemic bioavailability the same in humans as it is in rats? We don't know and if it were greater, then there would be a greater possibility for systemic adverse effects. I discounted the c.v. effects earlier because how could a non-absorbed drug have a systemic effect? What about bioavailability of this oral drug in patients with recent bowel surgery, a point I have raised earlier?

2. Are the mu opioid receptors in the GI tract expressed on the luminal surface of the epithelium and is this where the drug is active, or is the drug absorbed through the mucosa, acting on the basolateral side or more likely, on the neuromuscular components of the bowel and prevented from systemic delivery by metabolism in the liver after transport via the portal circulation? If so, then co-administered drugs that interfere with hepatic detoxification would allow systemic delivery, and I wonder if the toxicology studies looked at this?

There are others but that will do to illustrate the point. We can't know everything and just have to do our best.

Biotech investing is not an easy business!

RE42
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News